Affiliations 

  • 1 Department of Internal Medicine, New York Medical College at Saint Michael's Medical Center, Newark, NJ, USA
  • 2 Department of Internal Medicine, Sparrow Health System and Michigan State University, East Lansing, MI, USA
  • 3 Department of Internal Medicine/Pediatrics, Beaumont Health, Royal Oak, MI, USA
  • 4 AIMST University, Bedong, Malaysia
  • 5 Department of Internal Medicine, University of Arizona-Banner University Medical Center, Tucson, AZ, USA
  • 6 Department of Internal Medicine, Crozer-Chester Medical Center, Upland, PA, USA
  • 7 Department of Cardiovascular Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA
  • 8 Department of Cardiovascular Medicine, New York Medical College at Saint Michael's Medical Center, Newark, NJ, USA
J Innov Card Rhythm Manag, 2024 Mar;15(3):5782-5785.
PMID: 38584749 DOI: 10.19102/icrm.2024.15035

Abstract

Sarcoidosis is a disease that involves multiple organs, including the cardiovascular system. While cardiac sarcoidosis has been increasingly recognized, the impact of sarcoidosis on atrial fibrillation (AF) is not well established. This study aimed to analyze the impact of sarcoidosis on in-hospital outcomes among patients who were admitted for a primary diagnosis of AF. Using the all-payer, nationally representative Nationwide Readmissions Database, our study included patients aged ≥18 years who were admitted for AF between 2017-2020. We stratified the cohort into two groups depending on the presence of sarcoidosis diagnosis. The in-hospital outcomes were assessed between the two groups via propensity score analysis. A total of 1031 (0.27%) AF patients with sarcoidosis and 387,380 (99.73%) AF patients without sarcoidosis were identified in our analysis. Our propensity score analysis of 1031 (50%) patients with AF and sarcoidosis and 1031 (50%) patients with AF but without sarcoidosis revealed comparable outcomes in early mortality (1.55% vs. 1.55%, P = 1.000), prolonged hospital stay (9.51% vs. 9.70%, P = .874), non-home discharge (7.95% vs. 9.89%, P = .108), and 30-day readmission (13.29% vs. 13.69%, P = .797) between the two groups. The cumulative cost of hospitalization was also similar in both groups ($12,632.25 vs. $12,532.63, P = .839). The in-hospital adverse event rates were comparable in both groups. Sarcoidosis is not a risk factor for poorer in-hospital outcomes following AF admission. These findings provide valuable insights into the effectiveness of the current guideline for AF management in patients with concomitant sarcoidosis and AF.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.